KDOQI 对 KDIGO 2022 版 CKD 糖尿病管理指南更新的解读
KDIGO 于 2022 年快速更新 CKD 糖尿病管理指南,KDOQI 工作组撰写评论解读其变化,重点分析对美国医疗的影响。更新反映 SGLT2 抑制剂和 GLP-1 受体激动剂从降糖药转变为心肾代谢治疗药物,并将 SGLT2 抑制剂起始 eGFR 下限降至≥20 mL/min/1.73m²,新增非甾体盐皮质激素受体拮抗剂非奈利酮。
要点
- SGLT2 抑制剂起始 eGFR 下限更新为≥20 mL/min/1.73m²
- SGLT2 抑制剂与 GLP-1 受体激动剂定位为心肾代谢治疗药物
- 非奈利酮获批用于降低心肾终点事件
核心结论
- KDIGO 2022 更新反映糖尿病合并 CKD 治疗药物从降糖向心肾代谢保护的转变。
- KDOQI 评论强调美国保险覆盖不平等和高费用限制新药可及性,可能加剧医疗差异。
研究设计与样本
- KDOQI 工作组受美国国家肾脏基金会召集,对 KDIGO 2022 更新撰写评论。
主要发现
- 多项临床试验显示糖尿病合并 CKD 患者肾脏和心血管 morbidity 与 mortality 显著改善。
- SGLT2 抑制剂和 GLP-1 受体激动剂从单纯降糖药演变为心肾代谢治疗药物。
- 非奈利酮作为首个 FDA 批准的非甾体盐皮质激素受体拮抗剂,用于降低心肾终点事件。
关键数值与推荐
- SGLT2 抑制剂起始 eGFR 下限为≥20 mL/min/1.73m²。
临床怎么用
- 临床应将 SGLT2 抑制剂和 GLP-1 受体激动剂用于心肾保护,而非仅降糖。
- 启动 SGLT2 抑制剂时 eGFR 可低至≥20 mL/min/1.73m²。
- 可考虑加用非奈利酮以降低心肾终点事件。
局限性
- 评论侧重美国医疗体系,其他国家适用性可能有限。
- 保险覆盖不平等和高成本限制新药在弱势人群中可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) guideline for diabetes management in chronic kidney disease (CKD) was updated in 2022, just 2 years after the previous update. The need for this rapid update is reflective of the recent and unprecedented positive results of numerous clinical trials aimed at reducing kidney and cardiovascular morbidity and mortality in people with diabetes. The Kidney Disease Outcomes Quality Initiative (KDOQI) work group for diabetes in CKD, convened by the National Kidney Foundation, provides herein a commentary on these changes, particularly the implications for health care in the United States. Changes to the KDIGO guideline mirror the evolution of sodium/glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists from purely antihyperglycemic agents to cardiorenal-metabolic therapeutics, and the lower estimated glomerular filtration rate of≥20mL/min/1.73m2 for SGLT2 inhibitor initiation. New data have also brought the addition of the first-in-class, Federal Drug Administration-approved nonsteroidal mineralocorticoid receptor antagonist finerenone as an agent to reduce cardiorenal end points. While there has been significant progress in innovation, there remain serious challenges to implementation, particularly in the United States where inequities in insurance coverage and high costs limit their use, particularly in vulnerable populations, ultimately widening health care disparities.
引用
- Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2023. PMID: 38142396. doi:10.1053/j.ajkd.2023.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。